NASDAQ:HSIC

Henry Schein Stock Forecast, Price & News

$80.37
-0.86 (-1.06 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.61
$81.49
50-Day Range
$73.80
$81.23
52-Week Range
$56.31
$83.45
Volume2.01 million shs
Average Volume959,806 shs
Market Capitalization$11.31 billion
P/E Ratio26.18
Dividend YieldN/A
Beta0.9
30 days | 90 days | 365 days | Advanced Chart
Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for Henry Schein and its competitors with MarketBeat's FREE daily newsletter.


Henry Schein logo

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

482nd out of 1,309 stocks

Medical & Hospital Equipment Industry

3rd out of 3 stocks

Analyst Opinion: 2.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

Is Henry Schein a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Henry Schein stock.
View analyst ratings for Henry Schein
or view top-rated stocks.

What stocks does MarketBeat like better than Henry Schein?

Wall Street analysts have given Henry Schein a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Henry Schein wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) posted its earnings results on Tuesday, August, 3rd. The company reported $1.11 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.13. The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.87 billion. Henry Schein had a net margin of 4.14% and a trailing twelve-month return on equity of 12.18%. The business's quarterly revenue was up 76.2% compared to the same quarter last year.
View Henry Schein's earnings history
.

How has Henry Schein's stock price been impacted by COVID-19 (Coronavirus)?

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HSIC stock has increased by 39.3% and is now trading at $80.37.
View which stocks have been most impacted by COVID-19
.

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 13th 2021, which permits the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its stock is undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein issued an update on its FY21 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of $3.85 for the period, compared to the Thomson Reuters consensus estimate of $4.15.

What price target have analysts set for HSIC?

3 Wall Street analysts have issued 1-year price targets for Henry Schein's shares. Their forecasts range from $90.00 to $95.00. On average, they anticipate Henry Schein's stock price to reach $92.00 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.
View analysts' price targets for Henry Schein
or view top-rated stocks among Wall Street analysts.

Who are Henry Schein's key executives?

Henry Schein's management team includes the following people:
  • Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 71, Pay $4.35M)
  • Mr. James P. Breslawski, Exec. Vice Chairman & Pres (Age 67, Pay $1.88M)
  • Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 64, Pay $1.51M)
  • Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Exec. Director (Age 68, Pay $1.56M)
  • Mr. Mark E. Mlotek, Exec. VP, Chief Strategic Officer & Exec. Director (Age 65, Pay $1.48M)
  • Mr. Ronald South, Chief Accounting Officer & VP of Corp. Fin.
  • Mr. Christopher Pendergast, Sr. VP & CTO (Age 58)
  • Ms. Carolynne Borders, VP of Investor Relations
  • Mr. Walter Siegel, Sr. VP & Gen. Counsel (Age 61)
  • John Lee, VP of Global Compensation & Benefits

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Henry Schein's key competitors?

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.34%), New York State Common Retirement Fund (0.91%), Ardevora Asset Management LLP (0.68%), Scout Investments Inc. (0.42%), Sumitomo Mitsui Trust Holdings Inc. (0.34%) and PGGM Investments (0.31%). Company insiders that own Henry Schein stock include Deborah Derby, Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein
.

Which institutional investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., New York State Common Retirement Fund, Unigestion Holding SA, State of Alaska Department of Revenue, Beacon Investment Advisory Services Inc., Zurcher Kantonalbank Zurich Cantonalbank , HGK Asset Management Inc., and Duncker Streett & Co. Inc.. Company insiders that have sold Henry Schein company stock in the last year include Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Steven Paladino, and Walter Siegel.
View insider buying and selling activity for Henry Schein
or view top insider-selling stocks.

Which institutional investors are buying Henry Schein stock?

HSIC stock was bought by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Ardevora Asset Management LLP, Lee Danner & Bass Inc., Boston Trust Walden Corp, DAVENPORT & Co LLC, Dupont Capital Management Corp, Victory Capital Management Inc., and IFM Investors Pty Ltd.
View insider buying and selling activity for Henry Schein
or or view top insider-buying stocks.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $80.37.

How much money does Henry Schein make?

Henry Schein has a market capitalization of $11.31 billion and generates $10.12 billion in revenue each year. The company earns $403.79 million in net income (profit) each year or $2.97 on an earnings per share basis.

How many employees does Henry Schein have?

Henry Schein employs 19,000 workers across the globe.

Does Henry Schein have any subsidiaries?

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, MEDIVET, Maddox Practice Group, Maravet, Marrodent, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

When was Henry Schein founded?

Henry Schein was founded in 1932.

What is Henry Schein's official website?

The official website for Henry Schein is www.henryschein.com.

Where are Henry Schein's headquarters?

Henry Schein is headquartered at 135 DURYEA RD, MELVILLE NY, 11747.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.